Speech-Language Pathologists in White Stone, NY Accepting Medicare
1 Speech-Language Pathologists found. Showing 1 - 1
 Rochelle Samantha Thomas, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: All In One Spot With Theratalk, 150-50 14th Rd, White Stone, NY 11357 Phone: 718-767-0091 |
News Archive
EU-funded project examines dietary habits in people with inadequate nutrition
Until now, we have had very little understanding of the extent of malnutrition in Europe, especially in populations at risk of poverty. Now, an EU-funded project calledCHANCE, aims to address the dietary habits in people with inadequate nutrition.
HHMI investigator to discuss how brain creates and controls emotions
Scientists know little about how the brain creates and controls emotions - an uncertainty that presents a major obstacle in the effort to develop treatments for emotional disorders. "The study of the brain science of emotion is in its infancy," says Howard Hughes Medical Institute (HHMI) investigator David Anderson, "yet emotional and psychiatric disorders continue to take an enormous toll on human society."
Researchers propose steps to enhance patient-physician communication to improve depression care
Because people with depression often do not recognize they have a problem or are unable to describe their distress, many do not seek treatment. About a quarter of those with major depression are undiagnosed, according to several studies, and fewer than half receive treatment.
Scientists can now observe enhancer activity in real embryo
As an embryo develops, different genes are turned on in different cells, to form muscles, neurons and other bodily parts. Inside each cell's nucleus, genetic sequences known as enhancers act like remote controls, switching genes on and off. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, can now see - and predict - exactly when each remote control is itself activated, in a real embryo.
Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK
The Journal of the American Academy of Dermatology (JAAD) has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses - 2.5% and 3.75% - administered daily on a 2-week treatment cycle. The study demonstrates that both formulations were superior to placebo, and that imiquimod 3.75% on a daily 2-week treatment cycle is superior to imiquimod 2.5% in treating actinic keratosis (AK) on a large surface area - the face or balding scalp.
› Verified 8 days ago